Gritstone bio, Inc.

Gritstone bio — Investor Presentation (January 2022)

47 slides from Gritstone bio's investor presentation, Jan 4, 2022

  1. Slide 1: Investor Presentation January 2022

    Investor Presentation January 2022 Exhibit 99.2

  2. Slide 2: Disclaimer

    Disclaimer This presentation and accompanying oral presentation, if any, contain forward-looking statements including, but not limited to, statements related to Gritstone bio, Inc.’s (“Gritstone”, “we” or “our”) preclinical and clinical product candidates, including GRANITE, SLATE, CORAL, and HIV pr

  3. Slide 3: Gritstone: Taking Immunotherapy to the Next Level

    Gritstone: Taking Immunotherapy to the Next Level Leveraging proprietary target identification & vaccine platform technologies Cash Position* as of Sept 30, 2021 ~$216.4M Proprietary Synergistic Technologies + In-House Manufacturing Capabilities Differentiated and Expansive Pipeline Premier Governme

  4. Slide 4: Dual Platform Approach Generates Distinct Product Candidates

    Dual Platform Approach Generates Distinct Product Candidates Novel, proprietary approach enables design of vaccines tailored to clinical need EDGE™ AI platform identification and design of antigens that induce robust CD8+ T cell responses EDGE™ AI PLATFORM Vaccine Delivery + Manufacturing 01 02 Mult

  5. Slide 5: Process: Designing Vaccines that Drive Both B and T Cell Immune Responses

    Process: Designing Vaccines that Drive Both B and T Cell Immune Responses Immunogen Design Pathogen Gene Selection Both surface antigens (for nAbs) and other viral genes (for T cell epitopes) Epitope Identification Immunogen Design Prioritized targets captured efficiently in vectors Careful design o

  6. Slide 6: Two "Mix & Match" Vaccine Platforms in the Clinic with Unique Attributes

    Two “Mix & Match” Vaccine Platforms in the Clinic with Unique Attributes Unique vectors to drive both antibodies and CD8+ T cells ChAd (Chimpanzee Adenovirus 68) Replication-Defective Virus Based on Chimpanzee Adenovirus 68 Drives rapid and substantial CD8+ T cell response Induces high, sustained le

  7. Slide 7: Differentiated Clinical Assets Across Technologies & Therapeutic Areas

    Program Target Indication Pre-clinical Phase 1 Phase 2 Phase 3 Anticipated Milestones Commercial Rights INFECTIOUS DISEASE CORAL SARS-CoV-2 Spike + TCE* COVID-19 BOOST (60+) 1Q2022 Data SARS-CoV-2 Spike + TCE* COVID-19 naïve & booster 1H2022 Data SARS-CoV-2 Spike + TCE* COVID-19 Immunocompromised Mi

  8. Slide 8: Infectious Disease: COVID-19 (CORAL), HIV

    Infectious Disease COVID-19 (CORAL) HIV

  9. Slide 9: COVID-19 Remains a Global Pandemic

    COVID-19 Remains a Global Pandemic Omicron is now the globally dominant variant; what’s next? *Adapted from Financial Times Coronavirus Tracker, Jan 2, 2022

  10. Slide 10: Omicron Mutations Are Centered on Spike

    Omicron Mutations Are Centered on Spike…. E=Envelope M=Membrane N=Nucleoprotein Comparison of Mutations Within Variants to the Original SARS-CoV-2 Wild Type Strain Sources: outbreak.org & cov-lineages.org

  11. Slide 11: Omicron Reduces Neutralizing Potency of Reference-Strain Spike Vaccine Antibodies

    …And Reduce The Neutralizing Potency of Reference-Strain Spike Vaccine-Elicited Antibodies Neutralization potency of sera from BNT162b2-vaccinated subjects Cele, et. al., medRxiv, 2021; Sources: outbreak.org & cov-lineages.org BNT162b2 + infection BNT162b2 only 1,321 41.4X 32 Potency of antibodies r

  12. Slide 12: New Vaccine Approach is Desired to Achieve Durable Immunity

    New Vaccine Approach is Desired to Achieve Durable Immunity Existing vaccine solutions have limitations as Spike rapidly mutates and variants of concern (VoC) emerge Vaccination Approach to VoC Ideal Solution 1Hansen et al. medRxiv 12/22/2021 Limitations Variant-specific Re-boost Protection across c

  13. Slide 13: T Cells Offer Potential Path to More Robust and Durable Immunity

    T Cells Offer Potential Path to More Robust and Durable Immunity Dates of articles above: “The T-Cell Covid Cavalry”, Dec 30, 2021; “Beyond the spike…”, Dec 20, 2021; “T Cells Might Be Our Bodies….”, Dec 14, 2021; “Covid-resistant people…”, Nov 10, 2021.

  14. Slide 14: samRNA: A Second-Generation mRNA Platform with Unique Attributes

    samRNA: A Second-Generation mRNA Platform with Unique Attributes Differentiated vector that drives robust antibody and CD8+ T cell responses Extended duration and magnitude of antigen expression Strong & potentially durable induction of neutralizing antibody & T cell immunity (CD4+ and CD8+) Dose sp

  15. Slide 15: CORAL Clinical Development Strategy

    Study Population Vaccine Location Construct n CORAL - BOOST Healthy volunteers ≥60 years previously vaccinated samRNA samRNA/samRNA UK & US SWT-TCE5 120 CORAL - IMMUNO-COMPROMISED B-cell deficient (hematologic malignancies, MS), previously vaccinated ChAd/samRNA ChAd/ChAd UK SWT-TCE5 20-30 CORAL - C

  16. Slide 16: CORAL-BOOST: samRNA as Boost Following Approved COVID-19 Vaccination

    CORAL-BOOST: samRNA as Boost Following Approved COVID-19 Vaccination Single dose of samRNA CORAL vaccine containing T cell epitopes and WT Strain Spike antigen samRNA SWT-TCE5 CORAL-BOOST Vaccine Candidate CORAL samRNA-SWT-TCE5 (GRT-R910) Population Healthy volunteers ≥60 years Previously vaccinated

  17. Slide 17: Cohort 1: Subject Demographics

    Cohort 1: Subject Demographics Subject ID Gender Age Weeks post 2nd Vaxzevria dose 0001 M 63 30 0002 F 64 30 0003 F 63 22 0004 M 63 22 0005 M 69 25 0007 F 63 24 0008 M 81 25 0009 F 75 23 0014 M 75 27 0015 M 72 22

  18. Slide 18: samRNA Boost Shown to Have Favorable Safety and Tolerability Profile

    samRNA Boost was Shown to Have a Favorable Safety and Tolerability Profile at 10µg in Healthy Volunteers ≥60 yrs No unexpected reactogenicity or safety events 1 AE of recurrence of asthma and 1 AE of recurrence of muscle spasm in 10 µg dose cohort Database snapshot as of 11/29/2021 Percentage of Par

  19. Slide 19: Single 10µg samRNA Boost Induced Potent Neutralizing Antibody Response

    Single 10µg samRNA Boost Dose Post Vaxzevria Two Dose Series Induced Potent Neutralizing Antibody Response Against SARS-CoV-2 *ID50 = Median infective dose; **Geomean ID50 titer values notated; Assays conducted using WHO international standards Treatment day = day 1 GRTS samRNA boost dose was admini

  20. Slide 20: Comparison Across Studies: 10µg samRNA Boost vs Moderna 100µg

    Comparison Across Studies: 10µg samRNA Boost Elicited Similar, Potent nAb Response to 100µg of Moderna (mRNA-1273) after AZ Primary Series Mean age: 64-65 yrs Adapted from Munro et al. Lancet 2021 1,621 2,368 1,344 80 70 80 Mean age: 69 yrs; n = 10 Neutralizing antibodies (geomean) against Wild Type

  21. Slide 21: Single 10µg samRNA Boost Induced a Broad, Potent nAb Response

    Single 10µg samRNA Boost Dose Induced a Broad, Potent nAb Response Wild Type Variant Beta Variant Delta Variant Treatment Day Treatment Day Treatment Day *ID50 = Median infective dose, **Geomean ID50 titer values notated – not studied head-to-head directly. Treatment day = day 1 GRTS samRNA boost do

  22. Slide 22: Single 10µg samRNA Boost Induced Broad Anti-Spike IgG Response

    Single 10µg samRNA Boost Dose Induced Broad Anti-Spike IgG Response ELISA-based assay assessing anti-Spike IgG concentration in arbitrary units (AU) per mL *Geomean AU/ml indicated Treatment day = day 1 GRTS samRNA boost dose was administered. Boxes and horizontal bars denote interquartile range (IQ

  23. Slide 23: samRNA Boost Drove Significant CD8+ T Cell Responses to Non-Spike Epitopes

    Single 10µg samRNA Boost was Shown to Drive Significant CD8+ T Cell Responses to Non-Spike Epitopes – Potential for Variant-Proof Immunity Mean 9.0 Mean 514.7 Minimal TCE5 epitope pools (stacked); background subtracted Box and whisker plot: 90% CI and median shown Post-IVS ELISPOT Proportion of resp

  24. Slide 24: Variant Mutations Had Minimal Impact on Gritstone Vaccine T Cell Epitopes

    As Expected, Variant Mutations Had Minimal Impact on Gritstone Vaccine T Cell Epitopes (TCE) E=Envelope M=Membrane N=Nucleoprotein *2 epitopes impacted in 10% of Omicron isolates; 0 epitopes impacted in other isolates ** N-TCE11: no epitopes impacted in TCE but 6 Omicron mutations in 419 AA Nucleopr

  25. Slide 25: Spike-Specific T Cell Responses Boosted after Single 10µg Dose of samRNA

    Spike-Specific T Cell Responses Boosted after Single 10µg Dose of samRNA Ex vivo ELISpot 55 *Geometric mean is indicated Box and whisker plot: 90% CI and median shown 120 Spike overlapping peptide pools (stacked)

  26. Slide 26: CORAL-BOOST: Planned Study Expansion

    CORAL-BOOST: Planned Study Expansion Expanded study intended to explore effects of 2nd samRNA dose and assess different primary vaccine series Cohort 1 (UK) at 10 mg n = 10 (≥ 4 months after ChAdOx1) Cohort 2 (UK) at 30 mg n = 10 (≥ 4 months after ChAdOx1) Optional second dose samRNA SWT-TCE5 at 30

  27. Slide 27: Gritstone's Platform is Highly Adaptable to Protect Against Variants

    Gritstone’s Platform is Highly Adaptable to Protect Against Variants Coronavirus evolution may give rise to additional pandemic strains 2001 2012 2019 202X SARS MERS COVID-19 Emerging Variants of Concern (Omicron)/ Pan-coronavirus

  28. Slide 28: Collaboration with Gilead Under their HIV Cure Program

    Collaboration with Gilead Under their HIV Cure Program to Research and Develop Vaccine-based HIV Immunotherapy Treatment Deal value of up to $785 million plus royalties Gilead and Gritstone to develop an HIV-specific therapeutic vaccine Gritstone’s vaccine platform technology: adenoviral and self-am

  29. Slide 29: Neoantigen Derived Cancer Immunotherapy: Individualized and "Off the Shelf"

    Neoantigen Derived Cancer Immunotherapy Individualized and “Off the Shelf”

  30. Slide 30: Therapeutic Hypothesis: Neoantigen-Specific CD8+ T Cells for Solid Tumors

    anti-PD-(L)1 mAb High Tumor Mutation Burden High PD-L1 Exhausted T cells anti-PD-(L)1 mAb Neoantigen-specific immunotherapy de novo T cells ChAd* Vector Prime Boosts Self-Amplifying mRNA Re-activated T cells Melanoma MSI high tumors Microsatellite-stable Colorectal Cancer Gastroesophageal adenocarci

  31. Slide 31: GRANITE and SLATE Phase 1/2 Studies Support Advancement into Randomized Phase 2 Trials

    GRANITE and SLATE Phase 1/2 Studies Support Advancement into Randomized Phase 2 Trials GRANITE & SLATE programs demonstrated promising efficacy with tolerable safety across solid tumors GRANITE individualized Colorectal (MSS) Lung Gastric SLATE off-the-shelf High Frequency KRASmut Lung Pancreatic Co

  32. Slide 32: Phase 1/2 Study of GRANITE in Combination with Checkpoint Blockade

    Phase 1/2 Study Evaluating the Safety, Immunogenicity, and Clinical Activity of GRANITE in Combination with Checkpoint Blockade GRT-C901 GRT-C901 = chimpanzee adenovirus encoding 20 neoantigens GRT-R902 = self-amplifying mRNA in lipid nanoparticles encoding same neoantigens as GRT-C901 ChAd Vector P

  33. Slide 33: Safety: Immunotherapy Well-Tolerated in Previously Treated Metastatic Solid Tumors

    Safety: Immunotherapy Well-Tolerated In Patients with Previously Treated Metastatic Solid Tumors No patients experienced a DLT, no vaccine discontinuations due to TRAEs, and most common AEs comprise low-grade fever and injections site reactions, consistent with potent vaccine Demographics and Tumor

  34. Slide 34: PD-L1 mRNA Expression vs. Tumor Mutational Burden

    PD-L1 mRNA expression vs. Tumor Mutational Burden IFN-g score was obtained by averaging IFN-g established gene set z-scores calculated across GRANITE and relevant PANCAN TCGA tissue types (LUAD, LUSC, COAD, SKCM): J Clin Invest. 2017;127(8):2930-2940 GRANITE TCGA TMB calculated based on all somatic

  35. Slide 35: Immunogenicity: GRANITE Consistently Induces Neoantigen-specific T-cells

    Immunogenicity: GRANITE Consistently Induces Neoantigen-specific T-cells Lack of T cells in patients prior to treatment reflective of poor immunogenicity Baseline On-Treatment Patient ID ex vivo ELISpot G5: no samples available (patient died)

  36. Slide 36: Efficacy: Clinical Activity in Previously Treated MSS-CRC

    Efficacy: Clinical Activity in Previously Treated MSS-CRC Based on Partial and Complete Molecular Responses and Associated Prolonged PFS Tumor lesion shrinkage also observed in multiple patients – often over many months Best ctDNA molecular response (% ctDNA change from baseline)1,2 SD per RECIST fo

  37. Slide 37: Efficacy: Molecular Response Associated with Increased OS

    Efficacy: Molecular Response (ctDNA reduction) is Associated with Increased OS (>17 vs 7.8 months) MSS-CRC All (n=121) No Molecular Response (n=5) Molecular Response (n=4) Median Overall Survival (months) 8.7 7.8 Not reached (>17) Median iPFS per iRECIST (months) 3.9 2.0 11.8 Median PFS per RECIST (

  38. Slide 38: G8 Case Study: Lung CT Shows Transient Lesion Expansion at Week 8

    G8 Case Study: Lung CT Shows Transient Lesion Expansion at Week 8 (T Cell Infiltration?) Then Contraction Week 8 Week 16 Baseline Week 48

  39. Slide 39: GRANITE Clinical Development Strategy

    GRANITE Clinical Development Strategy Based on Ph1/2 data, we are advancing GRANITE into 2 randomized, controlled clinical trials in MSS-CRC Study Phase N Population Induction Maintenance Primary Endpoint Study Phase N Population Induction Control Arm Treatment Arm GRANITE - 1L 2 80 1st Line MSS-CRC

  40. Slide 40: SLATE Product Targeting KRAS Mutants

    SLATE Product Targeting KRAS Mutants One Product – Many Selected Patients Common Driver Mutation Class I HLA Molecule KRAS SLATE Patient Selection for KRAS mutations Lung Adeno SLATE Eligible KRAS Mutation CRC SLATE Eligible KRAS Mutation PDA SLATE Eligible KRAS Mutation Pancreatic Ductal Adenocarci

  41. Slide 41: Safety: SLATE Immunotherapy Well-Tolerated in Previously Treated Metastatic Solid Tumors

    Safety: Immunotherapy Well-Tolerated In Patients with Previously Treated Metastatic Solid Tumors SLATE Baseline Characteristics n=26 Age: mean (range) 59 (33-83) Gender: Female/Male 16/10 Tumor Types Non-small cell lung cancer 13 Median number of prior therapies (range) 2 (1-4) Prior anti-PD-(L)1 th

  42. Slide 42: Efficacy: Several NSCLC Patients Experienced Decrease in ctDNA

    Efficacy: Several NSCLC Patients Experienced Decrease in ctDNA Including Patient with High Baseline Levels Patient​ Mutation​ Baseline ctDNA (mutated hGE/mL)​ S1​ G12C​ 124.64​ S2​ G12C​ 26.92​ S3​ G12C​ Not detectable​ S6​ G12D​ 21.12​ S10​ Q61H​ 77.23​ S14​ G12D​ Not detectable​ S26​ G12C​ 3386.05

  43. Slide 43: Case Study – S26: Unconfirmed Partial Response

    Case Study – S26: Unconfirmed Partial Response with Clear Reduction in Liver and Lung Lesions Baseline Week 8 Week 16 113 mm* 95 mm* (-16% relative to baseline) 61 mm* (-46% relative to baseline) *Sum of longest diameters of two target lesions

  44. Slide 44: SLATE: KRASmut Antigenic Cassette Induces Potent T-Cell Responses

    SLATE: Version 2 of the KRASmut Antigenic Cassette Induces Potent T-Cell Responses to Multiple KRAS Neoantigens – Phase 2 Trial Underway No T-cell response was observed in these transgenic mice with SLATE cassette version 1 Overnight stimulation with peptide pool containing 38 minimal epitopes. Back

  45. Slide 45: Gritstone Has its Own Fully Insourced Biomanufacturing Facility

    Gritstone Has its Own Fully Insourced Biomanufacturing Facility 43,000 sq. ft. manufacturing and testing facility in Pleasanton, CA LNP = Lipid Nanoparticles 2020: All Manufacturing Insourced Plasmid ChAd samRNA LNP, Fill/Finish Tumor sequencing Gritstone, MA Gritstone, CA

  46. Slide 46: Key Accomplishments and Anticipated Upcoming Milestones

    Key Accomplishments and Anticipated Upcoming Milestones Near-term catalysts provide multiple value inflection points for Gritstone 4Q 2021 1Q 2022 Initiate GRANITE Randomized Ph2/3 Trial in 1L maintenance MSS-CRC Pre-publish non-human primate viral challenge data CORAL-IMMUNOCOMPROMISED trial – MHRA

  47. Slide 47: Thank You

    Thank You ir@gritstone.com

Gritstone bio — Investor Presentation (January 2022) on 6ix